LEGN
- Legend Biotech Corporation
()
Overview
Company Summary
Legend Biotech Corporation (LEGN) is a global clinical-stage biopharmaceutical company focused on developing and commercializing innovative cell-based therapies for the treatment of various forms of cancer. The company specializes in utilizing a groundbreaking technology called chimeric antigen receptor (CAR) T-cell therapy.
CAR-T cell therapy involves engineering a patient's T cells (a type of white blood cell) to express CARs on their surface. These CARs enable the T cells to recognize and target specific cancer cells. Once injected back into the patient, the modified T cells can identify and destroy cancerous cells, offering a potentially curative treatment for certain types of cancers.
Legend Biotech has developed its flagship product, LCAR-B38M/JNJ-4528, which is a CAR-T cell therapy designed to target B-cell maturation antigen (BCMA), a protein present on the surface of multiple myeloma cells. This therapy has shown significant promise in clinical trials, demonstrating high response rates and durable remission in patients with relapsed or refractory multiple myeloma.
In addition to LCAR-B38M/JNJ-4528, Legend Biotech is also actively engaged in the development of other CAR-T therapies targeting different cancer types, such as acute lymphoblastic leukemia (ALL) and lymphoma. The company aims to advance its pipeline of innovative cell therapies to address unmet medical needs and provide new treatment options for patients with cancer.
Legend Biotech collaborates closely with its parent company, GenScript Biotech Corporation, as well as its strategic partner, Janssen Biotech, a subsidiary of Johnson & Johnson. Through these collaborations, the company has access to extensive research and development capabilities, manufacturing expertise, and global commercialization networks, enhancing its ability to bring novel cell therapies to market.